ProcDNA has released its latest ESMO 2025 Insights, providing a comprehensive analysis of the scientific discussions, treatment trends, and digital engagement shaping the future of lung cancer care. Leveraging its Auxo Conference Intelligence platform, the report transforms conference conversations into actionable intelligence for pharmaceutical and biotech organizations.

Drawing from over 40 million impressions, 5,000+ social media conversations, and engagement from more than 2,000 healthcare professionals, the analysis highlights the topics driving the greatest attention during the European Society for Medical Oncology (ESMO) Congress 2025.

The findings reveal that bispecific antibodies, antibody-drug conjugates (ADCs), and combination therapies dominated discussions, reflecting the industry's continued shift toward precision oncology. Significant attention was also given to evolving treatment approaches in non-small cell lung cancer (NSCLC), including advances in ivonescimab, TROP2-directed ADCs, and strategies to address EGFR resistance.

ProcDNA's Conference Intelligence platform combines AI-powered analytics, social listening, and scientific intelligence to help life sciences organizations monitor conference engagement in real time. The platform enables commercial, medical, and competitive intelligence teams to identify emerging research trends, understand key opinion leader (KOL) influence, and measure the impact of scientific communications.

By translating large volumes of conference data into meaningful insights, ProcDNA empowers organizations to make faster, evidence-based decisions that support product strategy, clinical development, and commercial planning.

As major scientific congresses continue to shape the future of healthcare innovation, ProcDNA remains committed to delivering timely intelligence that helps life sciences organizations stay ahead of emerging opportunities and evolving market dynamics.